SCANDONEST L Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Scandonest L, and what generic alternatives are available?
Scandonest L is a drug marketed by Deproco and is included in one NDA.
The generic ingredient in SCANDONEST L is levonordefrin; mepivacaine hydrochloride. There are two drug master file entries for this compound. Additional details are available on the levonordefrin; mepivacaine hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SCANDONEST L?
- What are the global sales for SCANDONEST L?
- What is Average Wholesale Price for SCANDONEST L?
Summary for SCANDONEST L
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 2 |
| DailyMed Link: | SCANDONEST L at DailyMed |
Recent Clinical Trials for SCANDONEST L
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Cairo University | N/A |
| Afshan Amjad Ali | Phase 2 |
US Patents and Regulatory Information for SCANDONEST L
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deproco | SCANDONEST L | levonordefrin; mepivacaine hydrochloride | INJECTABLE;INJECTION | 088388-001 | Oct 10, 1984 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
